| Literature DB >> 35737161 |
M L Filipenko1, I P Oskorbin2, D V Shamovskaya2, E A Kharpov2, A A Stepanov2, V V Romanov3, V V Kuznetsov3, U A Boyarskikh2, A A Kechin2, E V Pechkovsky4, A B Krivoruchko5, A M Ivanov5, N E Kushlinskii6, V V Vlasov2.
Abstract
We developed a new test system to detect the omicron variant of SARS-CoV-2 using allele-specific reverse transcription PCR and estimated the frequency of its detection in patients living in the Novosibirsk Region. Clinical samples were divided into 3 groups: samples collected from December 1 to December 30, 2021 (group 1; n=66), from December 30, 2021 to January 10, 2022 (group 2; n=20), and from January 11 to January 22, 2022 (group 3; n=101). Based on the identification of 5 mutations specific to SARS-CoV-2 (B.1.1.529), two systems of oligonucleotide primers and probes were developed for detecting this coronavirus genotype in clinical samples. Limit of detection (LOD95) was 4×103 genome equivalents per 1 ml of clinical sample for the first test system and 2×103 for the for the second test system. The omicron variant of SARS-CoV-2 was absent in group 1 of studied samples, but was detected in 20% (4/20) of group 2 samples and 88% of group 2 samples collected within less than 2 weeks of January 2022. Using developed test system, we showed that in less than 2 weeks the omicron variant has become dominant in patients, which confirms previously published data on its exceptional contagiousness.Entities:
Keywords: SARS-CoV 2; allele-specific reverse transcription PCR (AS-RT-PCR); coronavirus; mutations; omicron variant
Mesh：
Substances：
Year: 2022 PMID： 35737161 PMCID： PMC9218049 DOI： 10.1007/s10517-022-05524-0
Source DB: PubMed Journal: Bull Exp Biol Med ISSN： 0007-4888 Impact factor: 0.737